View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
February 16, 2018

The age of immortality

For the first time in human history the possibility of immortality, or at least drastically prolonged lifespans, is real.

For the first time in human history the possibility of immortality, or at least drastically prolonged lifespans, is real.

The question is, how will a society already struggling to deal with a rapidly increasing population cope with this imminent phenomenon?

Since the industrial revolution life expectancy has almost doubled as a result of numerous technological breakthroughs.

The steepest inclines in life expectancy have occurred following revolutions such as antibiotic development and vaccination programs1.

As the information age continues to expand and grow these technological advances are beginning to pale in insignificance to the healthcare capabilities we have now.

It is now possible to reliably and accurately re-introduce immune cells that are designed to track and kill cancer cells, to edit viral DNA out of cells genomes and to grow organs that can replace diseased or aged ones.

20 years younger?

Elizabeth Parrish, CEO of BioViva, claims to have successfully used gene therapy to reduce the biological age of her immune cells by 20 years.

This was achieved by silencing one protein, myostatin, and enhancing genes responsible for the enzyme telomerase, which is responsible for fixing our genetic code when our cells divide.

Although some scientists have scorned Parrish’s reported results the scientific principle remains sound, and the technology does exist.

It is more a question of whether correct procedure was followed than whether this technology is useful2.

Researchers at Harvard University also recently published a paper investigating the role of Nicotinamide adenine dinucleotide (NAD), a ubiquitous co-enzyme found in all living cells in DNA repair and resistance to damage from radiation and chemotherapy drugs.

The research team was keen to point out that what is beneficial in mice may not always be beneficial in humans.

Nonetheless, there was cautious optimism from Professor David Sinclair, who said “Our results unveil a key mechanism in cellular degeneration and aging, but beyond that they point to a therapeutic avenue to halt and reverse age-related and radiation-induced DNA damage”3.

What does this mean?

By 2030, over 800 million jobs could be lost to automation worldwide, a trend that, like life expectancy, will only increase with technological advancements4.

Some countries like Finland are currently experimenting with a universal basic income, which has so far allowed people to re-train and get back into work and attracted endorsements from futurists such as Elon Musk and tech giants like Mark Zuckerberg5.

Although this idea may seem outlandish to some and the full results will not be published until the end of 2018, there is clear sense in allowing people the means to take care of their own health and needs to reduce the long-term burden on health and welfare systems as people live longer and work less.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy